Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo

International Journal of Cancer

Volumn 116, Issue 5, 2005, Pages 686-691

  Fontana, Aurélie ^a   Filleur, Stéphanie ^b   Guglielmi, Julien ^a   Frappart, Lucien ^a   Bruno Bossio, Gabriella ^a   Boissier, Sandrine ^a   Cabon, Florence ^b   Clézardin, Philippe ^a  

^a INSERM   (France)

^b CNRS   (France)

Author keywords

Cancer; Metastasis; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; SCLEROPROTEIN; THROMBOSPONDIN 1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELL ASSAY; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPH NODE METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR ESCAPE; TUMOR VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSPONDIN 1; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23244462950     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20584     Document Type: Article

References (25)

1. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
2. Good DJ, Polverini PJ, Rastinejad F, Le-Beau MM, Lemons RS, Frazier WA, Bouck N. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-8.
3. Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-8.
4. De Fraipont F, Nicholson AC, Feige JJ, van Meir EG. Thrombospondins and tumor angiogenesis. Trends Mol Med 2001;7:401-7.
5. Lawler J, Demar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004;36:1038-45.
6. Rodriguez-Manzaneque JC, Lane TF, Onega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001;98:12485-90.
7. Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol 2001;159:1949-56.
8. Clézardin P, Frappart L, Clerget M, Pechoux C, Delmas P. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res 1993;53:1421-30.
9. Kodama J, Hashimoto I, Seki N, Hongo A, Yoshinouchi M, Okuda H, Kudo T. Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis. Clin Cancer Res 2001;7:2826-31.
10. Wakiyama T, Shinohara T, Shirakusa T, John AS, Tuszynski G. The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine- cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer. Histol Histopathol 2001;16:345-51.
11. Straume O, Akslen LA. Expression of vascular endothelial growth factor, its receptors (Flt-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001;159:223-35.
12. Tobita K, Kijima H, Dowaki S, Oida Y, Kashiwagi H, Ishii M, Sugio Y, Sekka T, Ohtani Y, Tanaka M, Inokuchi S, Makuuchi H. Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int J Oncol 2002;21:1189-95.
13. Gasparini G, Toi M, Biganzoli E, Dittadi R, Fanelli M, Morabito A, Boracchi P, Gion M. Thrombospondin-1 and -2 in node negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. Oncology 2001;60:72-80.
14. Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clézardin P, Bouck N, Gabon F. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev 2001;15:1373-82.
15. Pécheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, Clézardin P. Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002;16:1266-8.
16. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM, Clézardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54.
17. Lawler J, Derick LH, Connolly JE, Chen JH, Chao FC. The structure of human platelet thrombospondin. J Biol Chem 1985;260:3762-72.
18. Hasebe T, Sasaki S, Imoto S, Ochiai A. Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol 2000;156:1701-10.
19. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61:5090-101.
20. Ding I, Sun JZ, Fenton B, Liu WM, Kimsely P, Okunieff P, Min W. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in Mca-4 murine mammary carcinomas. Cancer Res 2001;61:526-31.
21. Bertin N, Clézardin P, Kubiak R, Frappart L. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res 1997;57:396-9.
22. Relf M, LeJeune S, Scott PAE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-9.
23. Hawighorst T, Oura H, Streit M, Janes L, Nguyen L, Brown LF, Oliver G, Jackson DG, Detmar M. Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Am J Pathol 2002;21:7945-56.
24. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004;5:13-7.
25. Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, Clezardin P, Gabon F. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003;63:3919-22.